You are here: Industry Insights > Takeda

News List

Takeda closes TiGenix acquisition for about $608m pharmaceutical-technology
August 03, 2018
Takeda Pharmaceutical has completed its purchase of all outstanding ordinary shares of Belgium-based TiGenix for approximately $608.84m (€520m), representing €1.78 per share.
Lack of blockbuster candidates at Takeda? Don’t worry, Shire has it covered fiercepharma
August 02, 2018
Takeda’s revenue of 449.8 billion Japanese yen ($4 billion) during the April-to-June quarter was flat compared to last year. But the challenge in analysts’ eyes is not sinking Velcade sales but a lack of up-and-coming products to buoy future revenue. Luck
After its recent funding round, HiFiBiO pens Takeda R&D collaboration fiercebiotech
August 01, 2018
HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.
Takeda signs antibody therapy deal with HiFiBiO pharmatimes
July 31, 2018
Takeda has signed a multi-target agreement with biotech HiFiBiO Therapeutics to enable the discovery of antibody therapies to potentially treat various gastrointestinal diseases, cancers and other disorders.
After its recent funding round, HiFiBiO pens Takeda R&D collaboration fiercebiotech
July 31, 2018
HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.
Takeda's also-ran ALK drug Alunbrig aims to challenge Pfizer with new first-line data fiercepharma
July 27, 2018
Takeda's Alunbrig now sits in the back seat in ALK+ non-small cell lung cancer, behind rivals from Pfizer, Novartis and Roche. But the company has been pushing to change that, and on Wednesday, that effort got a leg up from new data.
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC pharmatimes
July 27, 2018
Takeda’s Alunbrig has beaten Pfizer's Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Takeda's also-ran ALK drug Alunbrig aims to challenge Pfizer with new first-line data fiercepharma
July 26, 2018
Takeda's Alunbrig now sits in the back seat in ALK+ non-small cell lung cancer, behind rivals from Pfizer, Novartis and Roche. But the company has been pushing to change that, and on Wednesday, that effort got a leg up from new data.
US expands scope of Seattle Genetics’ Adcetris pharmatimes
July 23, 2018
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals pharmatimes
July 20, 2018
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page